Introduction

This page provides a comprehensive analysis of the known insider trading history of Michael Rosenblatt. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Michael Rosenblatt has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:AZTA / Azenta, Inc. Director 13,042
US:AXLA / Axcella Health Inc. Director 40,000
US:RUBY / Rubius Therapeutics, Inc. Director 25,000
US:MRK / Merck & Co., Inc. Exec V-P & Chief Med Officer 50,934
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Michael Rosenblatt. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Trading History

This table shows the complete list of insider trades made by Michael Rosenblatt as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-02-13 2024-02-12 4 AZTA Azenta, Inc.
Common
A - Award 2,465 13,042 23.31 65.93 162,517 859,859
2023-02-15 2023-02-13 4 AZTA Azenta, Inc.
Common Stock
A - Award 3,604 10,577 51.69
2022-06-09 2022-02-11 4 AZTA Azenta, Inc.
Common Stock
A - Award 1,922 6,973 38.05
2022-05-23 2022-05-19 4 AXLA Axcella Health Inc.
Stock Option (Right to Buy)
A - Award 40,000 40,000
2022-05-23 3 AXLA Axcella Health Inc.
Common Stock
3,053
2022-05-13 2022-05-12 4 RUBY Rubius Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 25,000 25,000
2021-11-15 2021-11-12 4 BRKS Brooks Automation, Inc.
Common Stock
S - Sale -2,831 5,051 -35.92 114.13 -323,102 576,471
2021-05-14 2021-05-13 4 BRKS Brooks Automation, Inc.
Common Stock
S - Sale -1,760 7,882 -18.25 90.00 -158,400 709,380
2021-05-13 2021-05-12 4 RUBY Rubius Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 25,000 25,000
2021-02-08 2021-02-05 4 BRKS Brooks Automation, Inc.
Common Stock
A - Award 1,760 9,642 22.33
2020-05-26 2020-05-21 4 RUBY Rubius Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 25,000 25,000
2020-02-13 2020-02-11 4 BRKS Brooks Automation, Inc.
Common Stock
A - Award 2,831 7,882 56.05
2019-05-28 2019-05-23 4 RUBY Rubius Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 25,000 25,000
2019-02-11 2019-02-08 4 BRKS BROOKS AUTOMATION INC
Common Stock
A - Award 4,033 5,051 396.17
2018-09-11 2018-09-07 4 BRKS BROOKS AUTOMATION INC
Common Stock
A - Award 1,018 1,018
2018-07-18 2018-07-17 4 RUBY Rubius Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 25,000 25,000
2016-05-12 2016-05-10 4 MRK Merck & Co., Inc.
Stock Option (right to buy)
A - Award 50,934 50,934
2016-02-24 2016-02-22 4 MRK Merck & Co., Inc.
Common Stock
A - Award 7,738 41,133 23.17 50.77 392,858 2,088,326
2015-05-05 2015-05-02 4 MRK Merck & Co., Inc.
Restricted Stock Unit
M - Exercise -3,818 0 -100.00 59.86 -228,545
2015-05-05 2015-05-02 4 MRK Merck & Co., Inc.
Common Stock
F - Taxes -1,980 32,554 -5.73 59.86 -118,523 1,948,661
2015-05-05 2015-05-02 4 MRK Merck & Co., Inc.
Common Stock
M - Exercise 3,818 34,534 12.43
2015-05-05 2015-05-01 4 MRK Merck & Co., Inc.
Stock Option (right to buy)
A - Award 46,440 46,440
2015-02-25 2015-02-23 4 MRK Merck & Co., Inc.
Common Stock
A - Award 5,001 30,477 19.63 58.30 291,558 1,776,835
2014-05-13 2014-05-09 4 MRK Merck & Co. Inc.
Stock Option (right to buy)
A - Award 41,265 41,265
2014-05-06 2014-05-04 4 MRK Merck & Co. Inc.
Restricted Stock Unit
M - Exercise -4,103 0 -100.00 58.22 -238,877
2014-05-06 2014-05-04 4 MRK Merck & Co. Inc.
Common Stock
F - Taxes -1,799 24,921 -6.73 58.22 -104,738 1,450,888
2014-05-06 2014-05-04 4 MRK Merck & Co. Inc.
Common Stock
M - Exercise 4,103 26,720 18.14
2014-02-26 2014-02-24 4 MRK Merck & Co. Inc.
Common Stock
A - Award 4,907 22,439 27.99 56.18 275,675 1,260,614
2013-05-08 2013-05-07 4 MRK Merck & Co. Inc.
Restricted Stock Unit
M - Exercise -4,479 0 -100.00 44.98 -201,465
2013-05-08 2013-05-07 4 MRK Merck & Co. Inc.
Common Stock
F - Taxes -2,323 17,072 -11.98 44.98 -104,489 767,900
2013-05-08 2013-05-07 4 MRK Merck & Co. Inc.
Common Stock
M - Exercise 4,479 19,395 30.03
2013-05-08 2013-05-06 4 MRK Merck & Co. Inc.
Stock Option (right to buy)
A - Award 48,309 48,309
2013-02-27 2013-02-25 4 MRK Merck & Co. Inc.
Common Stock
A - Award 5,392 14,776 57.46 42.52 229,268 628,276
2013-02-20 2013-02-19 4 MRK Merck & Co. Inc.
Restricted Stock Unit
M - Exercise -15,000 0 -100.00 41.42 -621,300
2013-02-20 2013-02-19 4 MRK Merck & Co. Inc.
Common Stock
F - Taxes -5,616 9,384 -37.44 41.42 -232,615 388,685
2013-02-20 2013-02-19 4 MRK Merck & Co. Inc.
Common Stock
M - Exercise 15,000 15,000
2012-05-04 2012-05-02 4 MRK Merck & Co. Inc.
Stock Option (right to buy)
A - Award 54,845 54,845
2012-05-04 2012-05-02 4 MRK Merck & Co. Inc.
Restricted Stock Unit
A - Award 3,818 3,818
2011-05-06 2011-05-04 4 MRK Merck & Co. Inc.
Stock Option (right to buy)
A - Award 55,970 55,970
2011-05-06 2011-05-04 4 MRK Merck & Co. Inc.
Restricted Stock Unit
A - Award 4,103 4,103
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)